Investor Presentaiton

Investor presentation First three months of 2017 Significant growth opportunities fuelled by strong R&D pipeline across all four strategic focus areas PHASE 1 LAI287 - QW basal insulin NN1406 Mealtime insulin G530S Glucagon analogue NN9838- Amylin analogue PHASE 2 Semaglutide - QD GLP-1 Anti-IL-21 and liraglutide Semaglutide QD GLP-1 Semaglutide NASH PHASE 3 OG217SC Oral GLP-1 N8-GP Long-acting rFVIII Somapacitan - QW GH² SUBMITTED Fast-acting insulin aspart (US) Semaglutide - QW GLP-1 N9-GP Long-acting rFIV 3 APPROVED¹ Levemir® NovoRapidⓇ NovoMix® Tresiba® NN9747 PYY analogue NN9277 GG-co-agonist NN9499 FGF21 obesity NN9423 - Tri-agonist 1706 NN7415 Concizumab NN7170 Sc N8-GP Diabetes Obesity & other Haemophilia Growth disorders 1 Approved in all triad markets (US, EU and Japan), unless noted 2 Study conducted in adult growth hormone disorder 3 Positive CHMP received in the EU GG: Glucagon GLP-1 changing diabetes® RyzodegⓇ XultophyⓇ (EU & US) VictozaⓇ FiaspⓇ (EU) SaxendaⓇ NovoSeven® NovoEight® NovoThirteenⓇ Norditropin® Slide 27 novo nordisk

View entire presentation